Cancer Family
Breast Neoplasm
CI-CAN-00000007Explore in graph →
Non-malignant2,895 active trials43 approved drugs310 evidence items
- NCIt
- C2910
- OncoTree
- BNNOS
- MeSH
- D000069584
- MeSH
- D001943
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000007Explore in graph →
Clinical trials
13,871 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05966584 | A Study to Prevent Rash in People Starting Alpelisib for the Treatment of Breast Cancer | terminated | Phase 2 | 1 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Aug 29, 2024 | clinicaltrials |
| NCT04123704 | Sitravatinib in Metastatic Breast Cancer | terminated | Phase 2 | 3 | Xiang ZhangOTHER | 1 | Aug 26, 2024 | clinicaltrials |
| NCT04835597 |
| Precision Performance Status Assessment in Breast Cancer Patients Receiving Neoadjuvant Chemotherapy |
| terminated |
| — |
| 27 |
| M.D. Anderson Cancer CenterOTHER |
| 1 |
| Aug 26, 2024 |
| clinicaltrials |
| NCT03674827 | Vaccine-Based Immunotherapy Regimen For NSCLC and TNBC | terminated | Phase 1 | 36 | PfizerINDUSTRY | 1 | Aug 23, 2024 | clinicaltrials |
| NCT03498716 | A Study Comparing Atezolizumab (Anti PD-L1 Antibody) In Combination With Adjuvant Anthracycline/Taxane-Based Chemotherapy Versus Chemotherapy Alone In Patients With Operable Triple-Negative Breast Cancer(IMpassion030) | terminated | Phase 3 | 2,199 | Hoffmann-La RocheINDUSTRY | 31 | Aug 21, 2024 | clinicaltrials |
| NCT04363892 | Combined Optical and Infrared Imaging for Early Prediction of Erythema During Breast and Chestwall Radiotherapy | terminated | N/A | 7 | Nova Scotia Health AuthorityOTHER | 1 | Aug 21, 2024 | clinicaltrials |
| NCT06065059 | Study to Evaluate TNG348 Alone and With a PARP Inhibitor in Patients With BRCA 1/2 Mutant or HRD+ Solid Tumors | terminated | Phase 1 / Phase 2 | 7 | Tango Therapeutics, Inc.INDUSTRY | 1 | Aug 13, 2024 | clinicaltrials |
| NCT03387085 | QUILT-3.067: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With TNBC Who Have Progressed on or After Standard-of-care Therapy. | terminated | Phase 1 / Phase 2 | 9 | ImmunityBio, Inc.INDUSTRY | 1 | Aug 9, 2024 | clinicaltrials |
| NCT05156606 | Testosterone & Tamoxifen Trial(T&T) | terminated | N/A | 5 | University Medical Center GroningenOTHER | 1 | Aug 9, 2024 | clinicaltrials |
| NCT03127098 | QUILT-3.040: ETBX-011 (Ad5 [E1-, E2b-]-CEA(6D)) Vaccine in Combination With ALT-803 (Super-agonist IL-15) in Subjects Having CEA-Expressing Cancer | terminated | Phase 1 / Phase 2 | 3 | NantCell, Inc.INDUSTRY | 1 | Aug 6, 2024 | clinicaltrials |
| NCT06126003 | Gut and Tumor Microbiome in Patients With Early Stage (II-III), Locally Advanced or Advanced ER-positive and HER2-negative Breast Cancer. | terminated | — | 2 | BioCorteX IncINDUSTRY | 1 | Aug 2, 2024 | clinicaltrials |
| NCT04395339 | GM1 Prophylaxis for WBRT Related Cognitive Dysfunction(GLORY) | terminated | Phase 3 | 51 | Sun Yat-sen UniversityOTHER | 1 | Aug 1, 2024 | clinicaltrials |
| NCT05239663 | GM1 Prophylaxis for Post-chemotherapy Cognitive Impairment in Patients With Early Operable Breast Cancer | terminated | Phase 3 | 76 | Sun Yat-sen UniversityOTHER | 1 | Aug 1, 2024 | clinicaltrials |
| NCT05068726 | Clinical Utility of FES F18 PET/CT in Metastatic Breast Cancer Patients | terminated | — | 51 | GE HealthcareINDUSTRY | 1 | Jul 31, 2024 | clinicaltrials |
| NCT06084676 | Organoid Model Predictive of Response to Immunotherapies | terminated | — | 1 | Indiana UniversityOTHER | 1 | Jul 17, 2024 | clinicaltrials |
| NCT04072393 | Cardiac Rehabilitation for Patients Receiving Radiation Therapy for Thoracic Cancers | terminated | N/A | 24 | Washington University School of MedicineOTHER | 1 | Jul 12, 2024 | clinicaltrials |
| NCT01855607 | Topical Menthol for the Treatment of Chemotherapy Induced Peripheral Neuropathy | terminated | Phase 2 | 12 | Columbia UniversityOTHER | 1 | Jul 11, 2024 | clinicaltrials |
| NCT02096588 | Detection and Prevention of Anthracycline-Related Cardiac Toxicity With Concurrent Simvastatin | terminated | Phase 2 | 34 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Jul 9, 2024 | clinicaltrials |
| NCT03685591 | PF-06952229 Treatment in Adult Patients With Advanced Solid Tumors | terminated | Phase 1 | 49 | PfizerINDUSTRY | 1 | Jun 26, 2024 | clinicaltrials |
| NCT03393741 | Pharmacodynamic Biomarkers of Standard Anti-microtubule Drugs as Assessed by Early Tumor Biopsy | terminated | — | 5 | University of Wisconsin, MadisonOTHER | 1 | Jun 25, 2024 | clinicaltrials |
| NCT00123799 | Study of Fluorodeoxyglucose (FluGlucoScan) in Patients With Breast Cancer: Correlation With Histologic Findings of Sentinel Node Biopsies and Axillary Dissection | terminated | Phase 2 | 199 | AHS Cancer Control AlbertaOTHER | 1 | Jun 21, 2024 | clinicaltrials |
| NCT00358098 | Study to Determine the Utility of FES-PET and FDG-PET in the Prediction of Response to Hormone Therapy in Women With Estrogen Positive Metastatic Breast Cancer | terminated | — | 51 | AHS Cancer Control AlbertaOTHER | 1 | Jun 21, 2024 | clinicaltrials |
| NCT04862143 | Pilot Decentralized Clinical Trial in Men and Pre and Post-menopausal Women With Breast Cancer and a Specific Mutation (PIK3CA) Treated With Alpelisib in Combination With Fulvestrant(TELEPIK) | terminated | Phase 2 | 2 | Novartis PharmaceuticalsINDUSTRY | 1 | Jun 20, 2024 | clinicaltrials |
| NCT02876640 | Retinoid 9cUAB30 in Producing a Biologic Effect in Patients With Early Stage Breast Cancer | terminated | Phase 1 | 27 | National Cancer Institute (NCI)NIH | 1 | Jun 18, 2024 | clinicaltrials |
| NCT05163223 | Therapeutic Cancer Vaccine (AST-301, pNGVL3-hICD) in Patients With Breast Cancer(Cornerstone001) | terminated | Phase 2 | 10 | Aston Sci. Inc.INDUSTRY | 2 | Jun 17, 2024 | clinicaltrials |
| NCT00291304 | Magnetic Resonance Imaging (MRI) Correlation to Standard of Care Imaging and Pathology Correlation in Breast Carcinoma | terminated | Phase 2 | 72 | AHS Cancer Control AlbertaOTHER | 1 | Jun 14, 2024 | clinicaltrials |
| NCT03621982 | Study of ADCT-301 in Patients With Selected Advanced Solid Tumors | terminated | Phase 1 | 78 | ADC Therapeutics S.A.INDUSTRY | 3 | Jun 13, 2024 | clinicaltrials |
| NCT04927884 | A Study of Sacituzumab With Chemoimmunotherapy to Treat Advanced Triple-Negative Breast Cancer After Prior Therapies | terminated | Phase 1 / Phase 2 | 3 | ImmunityBio, Inc.INDUSTRY | 1 | Jun 12, 2024 | clinicaltrials |
| NCT00963547 | A Study of MK-2206 in Combination With Trastuzumab and Lapatinib for the Treatment of HER2+ Solid Tumors (MK-2206-015) | terminated | Phase 1 | 33 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Jun 4, 2024 | clinicaltrials |
| NCT01881880 | Value of Tomosynthesis in Breast Lesion Characterization and Breast Cancer Staging | terminated | N/A | 424 | University Hospital, MontpellierOTHER | 1 | May 29, 2024 | clinicaltrials |
| NCT03199040 | Neoantigen DNA Vaccine Alone vs. Neoantigen DNA Vaccine Plus Durvalumab in Triple Negative Breast Cancer Patients Following Standard of Care Therapy | terminated | Phase 1 | 18 | Washington University School of MedicineOTHER | 1 | May 28, 2024 | clinicaltrials |
| NCT04815291 | Streamlined Localization Using SCOUT® at Biopsy (STREAMLoc ) | terminated | N/A | 93 | Merit Medical Systems, Inc.INDUSTRY | 1 | May 21, 2024 | clinicaltrials |
| NCT05207514 | Compare the Efficacy and the Safety of Taxotere and Nanoxel M as Neoadjuvant Chemotherapy in Breast Cancer | terminated | Phase 3 | 26 | Samyang Biopharmaceuticals CorporationINDUSTRY | 1 | May 17, 2024 | clinicaltrials |
| NCT04655573 | A Pilot Study of a Micro-Organosphere Drug Screen Platform to Lead Care in Advanced Breast Cancer | terminated | — | 7 | Duke UniversityOTHER | 1 | May 16, 2024 | clinicaltrials |
| NCT04726332 | Study of XL102 as Single-Agent and Combination Therapy in Subjects With Solid Tumors (QUARTZ-101) | terminated | Phase 1 | 52 | ExelixisINDUSTRY | 1 | May 14, 2024 | clinicaltrials |
| NCT04927910 | Self-applied Acupressure for Arthralgia-fatigue-sleep Disturbance in Breast Cancer | terminated | Phase 2 | 21 | The Hong Kong Polytechnic UniversityOTHER | 1 | Apr 26, 2024 | clinicaltrials |
| NCT01199367 | Safety, Tolerability, and Efficacy Study in Subjects With Advanced or Metastatic Breast Cancer | terminated | Phase 1 | 11 | Kyowa Kirin Co., Ltd.INDUSTRY | 1 | Apr 25, 2024 | clinicaltrials |
| NCT05134194 | A Study of Camrelizumab in Combination With Chemotherapy Regimen Comparative Chemotherapy Regimen for Metastatic Triple-negative Breast Cancer | terminated | Phase 3 | 1 | Suzhou Suncadia Biopharmaceuticals Co., Ltd.INDUSTRY | 1 | Apr 16, 2024 | clinicaltrials |
| NCT04469205 | Study to Assess the Impact of Personalized Coaching on the Time Period and Quality of Return to Work After Breast Cancer(OPTICOACH) | terminated | N/A | 69 | Institut CurieOTHER | 1 | Apr 9, 2024 | clinicaltrials |
| NCT02540330 | A Pre-Surgical PK Study of IM and Intraductally Delivered Fulvestrant(007) | terminated | Phase 2 | 3 | Atossa Therapeutics, Inc.INDUSTRY | 1 | Apr 3, 2024 | clinicaltrials |
| NCT03361800 | Window of Opportunity Trial of Entinostat in Patients With Newly Diagnosed Stage I-IIIC,TNBC | terminated | Early Phase 1 | 5 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Mar 25, 2024 | clinicaltrials |
| NCT04682431 | A Phase 1a/1b FIH Study of PY159 and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors | terminated | Phase 1 | 127 | Ikena OncologyINDUSTRY | 1 | Mar 22, 2024 | clinicaltrials |
| NCT04691375 | A Study of PY314 in Subjects With Advanced Solid Tumors | terminated | Phase 1 | 86 | Ikena OncologyINDUSTRY | 1 | Mar 22, 2024 | clinicaltrials |
| NCT04586335 | Study of CYH33 in Combination With Olaparib an Oral PARP Inhibitor in Patients With Advanced Solid Tumors. | terminated | Phase 1 | 24 | Haihe Biopharma Co., Ltd.INDUSTRY | 3 | Mar 21, 2024 | clinicaltrials |
| NCT04172597 | A Study of Poziotinib in Patients With Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) Activating Mutations in Advanced Malignancies | terminated | Phase 2 | 1 | Spectrum Pharmaceuticals, IncINDUSTRY | 1 | Mar 13, 2024 | clinicaltrials |
| NCT01616758 | Phase II Study of GTx024 in Women With Metastatic Breast Cancer | terminated | Phase 2 | 22 | GTxINDUSTRY | 1 | Mar 8, 2024 | clinicaltrials |
| NCT03709082 | Palbociclib in Estrogen Receptor Positive (ER+) Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast Cancer | terminated | Phase 1 / Phase 2 | 3 | University of Kansas Medical CenterOTHER | 1 | Mar 5, 2024 | clinicaltrials |
| NCT03878524 | Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial | terminated | Phase 1 | 2 | OHSU Knight Cancer InstituteOTHER | 1 | Mar 4, 2024 | clinicaltrials |
| NCT05065411 | Efficacy & Safety Evaluation of Enobosarm in Combo With Abemaciclib in Treatment of ER+HER2- Metastatic Breast Cancer(VERU-024) | terminated | Phase 3 | 5 | Veru Inc.INDUSTRY | 1 | Feb 26, 2024 | clinicaltrials |
| NCT05458427 | Dedicated Breast CT for Diagnosis of Breast Cancer | terminated | — | 210 | Radboud University Medical CenterOTHER | 1 | Feb 26, 2024 | clinicaltrials |
Data updated 23 days agoSource updated Aug 29, 2024source: clinicaltrials